ArticleJournal of diabetes research2026
A Pilot Study of Urinary Cubilin Shedding in Type 1 Diabetes Mellitus: A Potential Biomarker to Predict Nephropathy.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Pilot Study of Urinary Cubilin Shedding in Type 1 Diabetes Mellitus: A Potential Biomarker to Predict Nephropathy.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering the low sensitivity of microalbuminuria and the increasing prevalence of diabetic nephropathy, biomarker discovery is a priority in diabetes research. We have previously reported increased urinary cubilin shedding preceding microalbuminuria in patients with Type 1 diabetes. In this study, we investigated the predictive value of urinary cubilin as a biomarker in diabetic nephropathy utilizing urine samples collected in one of the largest prospective cohort studies of Type 1 diabetes, Pittsburgh Epidemiology of Diabetes Complications. We measured urinary cubilin by ELISA in urine samples of the participants with normal kidney function and normoalbuminuria obtained at recruitment. Patients were stratified into three groups based on their disease course during a follow-up of > 20 years. Group 1 preserved normal kidney function and normoalbuminuria, Group 2 preserved kidney function but developed macroalbuminuria, and Group 3 progressed to have a > 40% decrease in kidney function during follow-up. We demonstrated that urinary cubilin normalized for creatinine predicted progressive diabetic nephropathy with an area under the receiver operating characteristic curve of 0.81. The urinary cubilin:creatinine ratio was marginally significant across the three groups evaluated by the Kruskal-Wallis test (p = 0.066). The adjusted p value for multiple comparisons of the urinary cubilin:creatinine ratio in comparing the group with > 40% decrease in kidney function and the other two groups was 0.05. The urine cubilin:creatinine ratio between the group with > 40% decrease in GFR and preserved kidney function was significant, with a p value of 0.017. We propose that urinary cubilin can be a promising biomarker to predict progressive diabetic nephropathy in patients with Type 1 diabetes. Studies involving larger patient populations are warranted to further validate urinary cubilin shedding as a novel biomarker in predicting progressive diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.